Salvage chemotherapy for relapsed or refractory non-Hodgkin's lymphoma with a combination of ACES (high-dose Ara C, carboplatin, etoposide and steroids) therapy
- 1 October 1996
- journal article
- clinical trial
- Published by Wiley in European Journal of Haematology
- Vol. 57 (4) , 320-324
- https://doi.org/10.1111/j.1600-0609.1996.tb01384.x
Abstract
No abstract availableKeywords
This publication has 7 references indexed in Scilit:
- Sequential peripheral blood progenitor cell transplantation after mobilization with salvage chemotherapy and G‐CSF in patients with resistant lymphomaAmerican Journal of Hematology, 1994
- Salvage therapy for non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide, and cisplatinCancer Chemotherapy and Pharmacology, 1992
- Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.Journal of Clinical Oncology, 1991
- Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)Blood, 1988
- IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapyBlood, 1982
- Reporting results of cancer treatmentCancer, 1981
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958